The ability for tumor cells to spread and metastasize to distant organs requires proteolytic degradation of extracellular matrix (ECM). This activity is mediated by invadopodia, actin-rich membrane protrusions that are enriched for proteases.
INTRODUCTION
In the past decades, significant advances have been made in the detection and treatment of breast cancer. However, tumor metastasis remains a major clinical obstacle for the survival of breast cancer patients. The development of an effective therapy for these patients thus relies on a better understanding on the mechanisms that drive metastatic tumor cells to disseminate from the primary site to distant organs.
In order for metastasis to occur, carcinoma cells must acquire the ability to degrade extracellular matrix (ECM), a process that allows tumor cells to intravasate from their original sites to blood stream and extravasate from circulation to distal organs (Chaffer and Weinberg, 2011) . Accumulating evidence has shown that invadopodia is a crucial structure for ECM degradation and subsequent tumor cell migration and invasion Eckert et al., 2011; Li et al., 2013; Paz et al., 2013; Seals et al., 2005) . Invadopodia are small dot-shaped actin-rich protrusions that are in close contact with ECM (Murphy and Courtneidge, 2011) .
Typical markers for invadopodia include cortactin and Tks5, which accumulate at the actin-rich dot-like structure of invadopodia. Cortactin is viewed as an integral molecule in invadopodia function that connects cellular signaling and the actin cytoskeleton (Murphy and Courtneidge, 2011; Weaver, 2008; Weed and Parsons, 2001 ). Cortactin is phosphorylated by Src and other tyrosine kinases (Boyle et al., 2007; Head et al., 2003; Huang et al., 1998; Kanner et al., 1990; Mader et al., 2011; Rajadurai et al., 2012) , and this allows for cortactin to bind to N-WASP, promoting Arp2/3-dependent actin polymerization that is required for invadopodia activity (DesMarais et al., 2004; Oser et al., 2009; Tehrani et al., 2007; Yamaguchi et al., 2005) . The proteolytic activity of invadopodia for degradation of ECM is conferred by proteases, ultimately allowing metastatic tumor cells to migrate through ECM and localize to distant organs. The membrane-anchored metalloprotease, MT1-MMP, is considered as a central player mediating invadopodia-dependent ECM degradation (Artym et al., 2006; Hotary et al., 2006; Murphy and Courtneidge, 2011) . However, how the metalloproteases are recruited to sites of invadopodia has been unclear.
In addition to acquiring invadopodia-mediated ECM degradation activity, metastatic tumor cells are frequently associated with abnormal activation of a developmental process, epithelial-mesenchymal transition (EMT) (Thiery and Sleeman, 2006; Yang and Weinberg, 2008) . Interestingly, it was recently reported that cells that have undergone EMT acquire invadopodia activity, suggesting that one of the key roles for tumor cells to undergo EMT during metastasis is perhaps to gain the ability to degrade ECM via invadopodia (Eckert et al., 2011) . The aberrant activation of EMT can be driven by a family of transcription factors such as Snail and Twist, and by the cytokine TGF. Recent work from our lab demonstrated that EMT is controlled at the level of alternative RNA splicing, an essential mechanism to generate protein diversity (Brown et al., 2011; Liu and Cheng, 2013; Xu et al., 2014) .
These studies relied on analysis of a critical cell surface molecule CD44. The CD44 gene is composed of nine constitutive exons, and nine or ten variable exons in the human or mouse genome, respectively, residing between the constitutive exons (Ponta et al., 2003) . Inclusion of one or more of the variable exons generates CD44 variant (CD44v), whereas skipping all of the variable exons produces CD44 standard (CD44s). We previously demonstrated that CD44 isoform switching occurs during EMT resulting in a shift in expression from CD44v in epithelial cells to CD44s in mesenchymal cells (Brown et al., 2011) . Importantly, when CD44 isoform switching is perturbed, cells can no longer undergo EMT (Brown et al., 2011) . Supporting the role of CD44s in EMT, recent work has also shown that CD44 depletion attenuates breast cancer bone metastasis (Hiraga et al., 2013) . While these studies introduce CD44s as a critical player in EMT and breast cancer, the mechanisms by which CD44, especially its splice isoforms, functions have not been well understood.
Given the fact that CD44s plays a critical role in EMT and that its function has been implicated in tumor cell invasion and breast cancer progression, we questioned whether the CD44s specific isoform plays an important role in invadopodia function, allowing for matrix degradation and tumor cell metastasis. The study presented here demonstrated that CD44s, but not CD44v, is a critical component in invadopodia.
Supporting these findings, we show that CD44s promotes breast tumor metastasis to the lung in a breast cancer metastasis model. Together, these results suggest that CD44s may serve as an effective therapeutic target for the treatment of metastatic breast cancer.
RESULTS

CD44 is localized in invadopodia in breast cancer cells and is required for invadopodia activity
Localization of actin, cortactin, and Tks5 in dot-like structure that has the ability to degrade matrix is characteristics of invadopodia (Murphy and Courtneidge 2011) . Human MDA-MB-231 breast cancer cells were used to examine whether CD44 is a component in the invadopodia structure. Immunofluorescence analysis showed that CD44 colocalized together with actin at regions where matrix was degraded, suggesting its localization in invadopodia ( Figure 1A top panel) . Further analyses also revealed that CD44 colocalized with cortactin and Tks5 ( Figure 1A middle and bottom panels, respectively) in matrix degradation area, supporting the notion that CD44 is a protein component in invadopodia. This observation was further confirmed in the human metastatic breast cancer BT-549 cells ( Figure S1A ).
To determine whether CD44 is functionally important in invadopodia activity in breast cancer cells, we knocked down CD44 by shRNA in MDA-MB-231 cells ( Figure 1B ). Co-staining of Tks5 and cortactin showed that approximately 40% of the control cells were positive for invadopodia ( Figure 1C,D) . In stark contrast, less than 5% of CD44-ablated cells exhibited invadopodia puncta. Furthermore, these CD44 knockdown MDA-MB-231 cells lost the ability to degrade matrix as gauged by gelatin degradation ( Figure 1E ,F), a phenotype that was also observed in HT1080 cells ( Figure S1B ,C,D). In addition, CD44 depletion caused a reduction in invasion ability scored by Boyden Chamber invasion assays ( Figure 1G ). Together, these results demonstrate that CD44 is required for invadopodia activity and tumor cell invasion.
CD44s is the major isoform associated with the invadopodia complex
An intriguing observation was that cells that form invadopodia, including MDA-MB-231, BT-549, and HT-1080, mainly express the CD44s isoform ( Figure   S2A ). By contrast, cells that predominantly express CD44v do not contain the invadopodia structure ( Figure S2A,B) . These results suggest that isoform specificity of CD44 determines its role in invadopodia. To test this hypothesis, CD44s and CD44v cDNAs were ectopically expressed in the CD44 knockdown MDA-MB-231 cells to levels comparable to that in the parental cells (Figure 2A ). We found that reconstitution of CD44s in the CD44-depleted cells fully rescued the impaired phenotype of invadopodia, as evidenced by the colocalization of Tks5 and cortactin or actin at sites of matrix degradation ( Figures 2B,S2C) . Quantification of numbers of cells that contain the invadopodia puncta as well as the extent of gelatin degradation area also supported these findings ( Figure 2C , top and bottom panels, respectively), where the reduction of invadopodia and matrix degradation in CD44 depleted cells was restored by reexpressing CD44s. By contrast, forced expression of CD44v was not able to rescue the impaired invadopodia phenotype ( Figures 2B,C, S2C ). These results were further confirmed by Z-sectioning images, showing that while both CD44s and CD44v were localized on the basal surface of the cell, CD44s protruded into sites of gelatin degradation ( Figure 2D ). CD44v-expressing cells, on the other hand, did not show any activity of matrix degradation ( Figure 2D ). Close examination of these CD44s and CD44v reconstituted cells showed that signals of actin and cortactin colocalization were noticeably lower at locations of dot-like structure in CD44v-reexpressing cells ( Figure S2D ,S2F), although the overall signal of colocalization appeared at similar level in both CD44s-and CD44v-reexpressing cells. Figure 2H) . Thus, these different sets of approaches demonstrate that the CD44s isoform, but not CD44v, is essential for mediating invadopodia activity.
We also tested whether CD44s is sufficient for invadopodia activity. We utilized a non-invasive breast cancer T47D cell line and generated T47D-SrcY527F cells. However, no invadopodia activity were observed when overexpressing CD44s in these cells (Figure S2G, S2H) . We suspect that this could be due to the lack of other critical components in the T47D-SrcY527F cells. For instance, Tks5 was shown to be insufficiently expressed in these cells .
Depletion of CD44 impairs cortactin phosphorylation
It has been well-established that phosphorylation of the adaptor protein cortactin is a key event for invadopodia function via initiation of actin polymerization.
In line with the importance of CD44s in invadopodia, CD44-depleted MDA-MB-231 cells showed reduced levels of phosphorylated cortactin, while the total level of cortactin or other invadopodia-associated proteins Tks5 and Src were not affected ( Figure 3A To determine the relationship between CD44s and cortactin in invadopodia function, we utilized the CD44s-reexpressing MDA-MB-231 cells that have had CD44 knocked down, as in these cells invadopodia activity is dependent on CD44s.
We found that knockdown of cortactin significantly decreased numbers of invadopodia and impaired matrix degradation activity in these cells ( Figure 3C ,D,E), suggesting that CD44s-mediated invadopodia activity also requires cortactin. Since cortactin phosphorylation is mediated chiefly by the Src kinase, we also treated the CD44s-reexpressing cells with the Src family inhibitor PP2 that blocks Src activity and thus cortactin phosphorylation. Consistent with the above observations, PP2 treatment abolished invadopodia activity for gelatin degradation ( Figure S3A ,B,C).
It is worth mentioning that CD44 knockdown did not affect Src activity at least under conditions where decreased cortactin phosphorylation was observed ( Figure S3D ). This prompted us to test the possibility that CD44s interacts with cortactin, facilitating cortactin phosphorylation. Immunoprecipitation assay showed that cortactin was detected in the CD44 immunoprecipitated fraction ( Figure 3F , left panel). Conversely, CD44s was also detected in the cortactin immunoprecipitated fraction ( Figure 3F , right panel). To examine whether this CD44 and cortactin interaction was CD44s isoform specific, we next performed immunoprecipitation experiments in the CD44s-reexpressing MDA-MB-231 cells as well as in MCF7 cells where CD44v is predominantly expressed ( Figure S2A ). We found both CD44 isoforms interact with cortactin and that the major form of cortactin in CD44s-interacted fraction was phosphorylated cortactin (Figure S3E, S3F) . Although CD44v exhibited a stronger binding affinity to cortactin ( Figure S3F ), nearly no detectable levels of p-cortactin were associated with CD44v ( Figure S3F ). Thus, these results suggest that the CD44s splice isoform preferentially interacts with phosphorylated cortactin.
Constitutive activation of Src restores cortactin phosphorylation but not invadopodia activity in CD44 knockdown cells
Given the above results that depletion of CD44 inhibits cortactin phosphorylation and invadopodia activity, we next examined whether restoring cortactin phosphorylation in the CD44 knockdown cells could rescue the impaired invadopodia phenotype. Forced expression of constitutively activated oncogenic SrcY527F restored cortactin phosphorylation in CD44-ablated MDA-MB-231 cells to levels comparable to that in control cells ( Figure 4A ). Interestingly however, SrcY527F expression failed to rescue the impaired invadopodia activity in the CD44 knockdown cells ( Figure 4B , Left panel). Roughly 11% of CD44-ablated cells contained invadopodia structure, whereas 65% of control cells were observed to contain the invadopodia structure ( Figure 4B , Right panel). Furthermore, a greater than 10-fold reduction in matrix degradation activity was shown in CD44-depleted SrcY527F-expressing cells as compared to control cells ( Figure 4C ).
Analysis of SrcY527F-expressing NIH3T3 cells further supported the above observations. While cortactin phosphorylation was at the same level in control and CD44 knockdown cells ( Figure 4D ), CD44 knockdown impaired invadopodia activity ( Figure 4E ) and reduced matrix degradation activity ( Figure 4F ). Together, these results indicate that, in addition to affecting cortactin phosphorylation, CD44s impacts pathways downstream of cortactin critical for invadopodia activity.
CD44s-dependent invadopodia activity requires MT1-MMP activity
Matrix degradation activity in invadopodia is mediated by metalloproteases. In accordance with this, treatment of MDA-MB-231 parental cells with a panmetalloprotease inhibitor GM6001 abolished gelatin degradation ( Figure 5A , top panel). Notably, GM6001 treatment also prevented gelatin degradation in the CD44s-reconstituted cells, in which the matrix degradation activity is mediated through CD44s ( Figure 5A ,B).
MT1-MMP is considered as the major protease responsible for the degradation activity in invadopodia (Artym et al., 2006; Hotary et al., 2006; Murphy and Courtneidge, 2011) . We found that CD44s-mediated matrix degradation requires the MT1-MMP protease activity because elimination of MT1-MMP by siRNA showed a 12-fold inhibition in gelatin degradation in the CD44s-reconstituted cells ( Figure   5C ,D,E).
CD44s and MT1-MMP interact at sites of invadopodia
It was previously reported that CD44 interacts with MT1-MMP for colocalization in lamellipodia, a 2-D structure designated for cell movement (Mori et al., 2002) . This observation led us to suspect the interaction between CD44 and MT1- 
CD44 is required for breast tumor cells metastasizing to distant organs
The above data demonstrate that CD44s acts as a critical component that mediates invadopodia activity. Given the functional link between invadopodia and tumor metastasis, the requirement for CD44s in metastasis was assessed using an 
DISCUSSION
Tumor metastasis remains as a major clinical obstacle for the treatment of breast cancer. Invadopodia serve as a critical cellular structure that engages tumor cells to degrade extracellular matrix, allowing them to disseminate from primary sites and metastasize to distant organs. In this study, we provide multiple lines of evidence demonstrating that the specific CD44s splice isoform plays a crucial role in invadopodia activity, leading to breast tumor metastasis. We show that CD44s interacts with cortactin and promotes its phosphorylation, a key step for actin polymerization in invadopodia. We also find that CD44s interacts with MT1-MMP at sites of invadopodia for proteolytic activity. Using a metastatic breast cancer mouse model, our data reveal that depletion of CD44s prevents breast cancer cells from disseminating to the lung. Hence, these results demonstrate that the CD44s splice isoform plays a crucial function in invadopodia function and breast tumor metastasis.
The CD44 gene encodes a family of cell surface proteins that is composed of the short CD44s isoform and the long variable-exon containing CD44v proteins, generated by alternative splicing. Previous studies have suggested a role for CD44 in invadopodia (Chabadel et al., 2007; Grass et al., 2013; Vikesaa et al., 2006) . However, whether specific isoforms of CD44 is functionally critical in invadopodia in cancer cells has not been determined. By performing isoform reconstitution assays and isoform specific shRNA approaches, our data demonstrate that the CD44s isoform, but not CD44v, constitutes the function of CD44 in invadopodia activity, emphasizing the splice isoform specificity in invadopodia activity. These results are in agreement with our previous findings that isoform switching of CD44 to the production of CD44s is essential for EMT (Brown et al., 2011) , a process that allows for the acquisition of invadopodia activity (Eckert et al., 2011) . We suspect that the CD44 isoform specific activities are controlled at least in part by their different interacting proteins, resulting in distinguished phenotypes in cells, an area of research that warrants further investigation. Cortactin phosphorylation is a key step for recruitment of actin-regulatory proteins Nck, N-WASP and Arp2/3, which initiate actin polymerization (DesMarais et al., 2004; Murphy and Courtneidge, 2011; Oser et al., 2009; Paz et al., 2013; Tehrani et al., 2007; Yamaguchi et al., 2005) , resulting in invadopodia activity. Our study showed that CD44s is required for cortactin phosphorylation, which is a downstream substrate of Src. It was previously shown that CD44 interacts with Src and treatment Journal of Cell Science • Advance article of hyaluronic acid, the CD44 ligand, promotes Src activity, cortactin phosphorylation, and tumor cell migration (Bourguignon et al., 2001 ). In our system, however, we have not found differences in levels of Src phosphorylation in control and CD44 knockdown cells, suggesting that Src activity as a whole remains consistent in these cells. We suspect that local Src activity is elevated in the invadopodia loci and CD44s brings cortactin to sites of phosphorylation. Supporting this view, we found that CD44s interacts with cortactin and they colocalize at invadopodia. This is also in line with our observation that CD44s is critical for Tks5 and cortactin colocalization, but in a much less extent, cortactin actin colocalization. We suspect that recruitment of Tks5, the scaffold protein of Src, may facilitate Src-mediated cortactin phosphorylation. An alternative mechanism could be that CD44 promotes cortactin phosphorylation via a CD44-dependent complex that contains receptor tyrosine kinases (RTKs) since CD44-RTK interaction has been previously reported (Ponta et al., 2003) . This idea is supported by recent studies showing that c-Met activation causes increased cortactin phosphorylation via a cortactin-Gab1 scaffold complex, resulting in invadopodia formation and matrix degradation (Rajadurai et al., 2012) .
While our results, together with previous findings, infer that CD44s promotes cortactin phosphorylation important for invadopodia activity, it would be of great interest to investigate the precise mechanisms by which CD44s affects cortactin phosphorylation and their relationships to invadopodia stages in future studies.
What is surprising is that upon restoring cortactin phosphorylation by ectopically expressing a constitutively activated SrcY527F mutant, CD44 knockdown cells remained to show impaired ability of invadopodia activity. This observation led to the findings that CD44s plays an essential role in MT1-MMP-mediated matrix degradation activity. The relationship between CD44 and MT1-MMP has been previously reported in the context of tumor cell invasion. For instance, MT1-MMP interacts with CD44, resulting in the shedding of CD44 and cell migration (Kajita et al., 2001; Suenaga et al., 2005; Wiesner et al., 2010; Zarrabi et al., 2011) . Whether the shedding of CD44s is involved in invadopodia will be of interesting to investigate. Moreover, It was previously shown that vesicle trafficking mediated by the v-SNARE VAMP7 is involved in MT1-MMP's degradation activity in invadopodia (Steffen et al., 2008) , and MT1-MMP exocytosis is required for matrix degradation (Monteiro et al., 2013) . Considering CD44s as a cell surface molecule that facilitates MT1-MMP to localize at the critical site for matrix degradation, it will be particularly interesting to shown that CD44s expression correlates with higher-grade breast tumors, while it has also been shown that CD44s correlates with increased survival (Brown et al., 2011; Diaz et al., 2005; Liu et al., 2005) . Furthermore, DNA methylation at the CD44 promoter methylation has been observed in prostate cancer (Lou et al., 1999; Woodson et al., 2006) . These seemingly un-unified results suggest the complexity of CD44 isoforms in cancer, perhaps due to context, stage, or tumor type differences, as well as the lack of a CD44s isoform specific antibody. These results suggest that isoform specificity must be considered for dissecting the role of CD44 in tumor invasion and metastasis.
In summary, our study presented here demonstrates the importance of a specific splice isoform CD44s in invadopodia activity. CD44s is required for cortactin phosphorylation and interacts with MT1-MMP at sites of invadopodia. In addition to our findings on splice isoforms in invadopodia activity, a recent study showed that a specific Tks5-long isoform, generated by alternative transcription start site, promotes invadopodia-mediated metastasis, whereas the Tks5-short isoform inhibits it (Li et al., 2013) . This and our studies suggest that biological processes are, in many cases, regulated at the levels of protein isoforms encoded by the same gene. Given the fact that greater than 90% of human genes undergo alternative splicing (Pan et al., 2008; Wang et al., 2008) , investigating the role of splice isoforms in cancer processes could lead to a better understanding of molecular mechanisms and the development of novel therapeutic interventions that target specific splice isoforms for the treatment of advanced cancer.
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MATERIALS AND METHODS
Cell Lines
Cell lines MDA-MD-231, MCF7, and HT-1080 were cultured with DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics. BT-549 cells were grown in RPMI 1640 supplemented with 10% FBS and antibiotics, NIH 3T3 cells were cultured with DMEM supplemented with 10% calf serum and antibiotics.
Retroviral or lentiviral infections were performed for generation of stable cell lines.
Plasmids and shRNA
The pBRIT-HA/Flag vector (AddGene) was used for generation of pBRIT-CD44-HA and pBRIT-MT1-MMP-HA plasmids. Subsequently, ZsGreen1 and DsRed sequences were cloned into Sal I restriction site of pBRIT-CD44-HA and pBRIT-MT1-MMP-HA, respectively. Plasmids expressing CD44s, CD44v containing variable exons v3-v10, and CD44 shRNA that target all CD44 isoforms have been described (Brown et al., 2011) . CD44s isoform specific shRNAs and cortactin shRNA were cloned in the pLKO.1 vector.
In vitro invasion assay
MDA-MB-231 and NIH3T3 cells were plated on a 6 cm plate to reach 30%-50% confluent next day. 24 hr after plating, cells were starved in 3 ml of 0.5% serum/DMEM. 24 hr after starvation, cells were trypsinized, washed with PBS twice, and resuspended in serum free DMEM. A total of 2. Beads were washed in lysis buffer 4 times. Proteins were eluted from beads using SDS sample buffer and analyzed on 10% SDS-PAGE gel.
Gelatin matrix degradation assay
Glass coverslips were incubated in 1M HCl at 55 o C overnight and washed with running distilled water in H2O for 4 hr then, coverslips were incubated with 50 μg/ml poly-L-lysine/PBS for 15 mins, washed with PBS 3 times. After incubating with 0.15% gluteraldehyde/PBS for 10 mins followed by 3 washes with PBS, coverslips were inverted onto 20 μl droplets that contained 0.1% Oregon Green® 488 conjugategelatin (Molecular Probes) and 0.2% porcine gelatin in a 1:9 ratio for 10 mins.
Coverslips were subsequently incubated in 5 mg/ml NaBH4 for 15 mins, rinsed in PBS, and incubated at 37 Table S1 .
Tumor xenografts and metastasis analysis
All animal experiments were performed in accordance with the protocols approved by
Institutional Animal Care and Use Committee (IACUC) of Princeton University. 4-6 weeks old female Athymic nude mice (NCI) were used to test lung metastasis development with LM2 and sublines. Lateral tail vein intravenous injection of tumor cells were performed as described (Chakrabarti et al., 2012) . For luciferase labeled LM2 cells, development of metastases was monitored by BLI with the IVIS Imaging System (Caliper Life Sciences) and analyzed with Living Image software (Caliper Life Sciences) as described (Chakrabarti et al., 2012) .
Statistical analysis
All raw measurements were presented as mean ± SD (standard error) as indicated. P values were calculated using student t-test for two-group comparison or one-way Anova for comparison of three or more groups. 
